TNF Inhibitor denied as not medically necessary by Florida Blue?

Florida Blue uses Prime Therapeutics or CVS Caremark depending on plan line. Step therapy through preferred biosimilar.

FL Statute 627.42393 limits step therapy when prior failure documented. Demand peer-to-peer review. Cite continuity-of-care for stable patients.

## Why Florida Blue Denies TNF Inhibitors for Medical Necessity

Florida Blue requires that all TNF inhibitor prescriptions meet its published medical-necessity criteria before coverage is approved. These criteria are specific to each drug and each qualifying diagnosis — rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and others each have their own requirements. A medical-necessity denial means Florida Blue's reviewer determined that your submitted documentation did not establish that your clinical situation satisfies all of the coverage criteria, which typically include a confirmed qualifying diagnosis, documented disease severity, and evidence that required prior treatments have been tried.

## Why This Denial Is Appealable

Medical-necessity denials hinge on documentation, not usually on clinical ineligibility. Most patients prescribed a TNF inhibitor by a specialist have a medically appropriate reason — the challenge is translating that clinical picture into the specific language and evidence format that Florida Blue's policy requires. Specialty-society guidelines from organizations such as the American College of Rheumatology (ACR), the American Gastroenterological Association (AGA), or the American Academy of Dermatology (AAD) provide clinical frameworks that often align with insurer criteria and strengthen appeals.

## Federal Appeal Rights

• Internal appeal: Florida Blue must provide a full-and-fair review under Florida's insurance code and, for employer-sponsored plans, ERISA §503. The reviewer must be different from the person who made the original decision and must not be subordinate to them.
• External review (ACA §2719): After exhausting the internal process, you have the right to independent external review, typically within four months of the final internal denial.
• Expedited review: If your condition is urgent — active flare, risk of irreversible joint damage, or severe disease activity — request expedited internal and external review simultaneously. Florida Blue is generally required to respond within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation: Specialist notes, laboratory results, imaging, or pathology confirming the qualifying diagnosis and its severity in objective terms. 2. Prior-treatment history with outcomes: A dated, outcome-documented list of each required prior therapy — including why it was discontinued (inadequate response, adverse effect, or clinical contraindication). 3. Current disease severity: Recent chart notes from your treating physician documenting active disease using the assessment tools standard for your condition. 4. Prescriber medical-necessity letter: A detailed letter from your specialist that addresses each Florida Blue coverage criterion, cites the relevant specialty-society guideline, and maps each requirement to a specific fact in your medical record. 5. Florida Blue coverage policy: Request the exact medical policy document used to deny your claim. Read every criterion and ensure your appeal responds to each one.

## Criteria-Mapping Structure

| Florida Blue Policy Requirement | Your Chart Evidence | |---|---| | Qualifying diagnosis confirmed | [Diagnosis, confirming test/note, date] | | Disease severity meets policy standard | [Physician note, assessment tool result, date] | | Required prior therapies tried and failed | [Each drug, dates, outcome] | | Prescriber medical-necessity attestation | [Letter date, specialty, credentials] |

Submit this table as part of your appeal letter. Florida Blue reviewers and external reviewers find criterion-by-criterion responses far easier to evaluate than general narrative letters — which significantly improves the chance of approval.